Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Pfizer Inc | 36 |
| 2 | Imperial Brands PLC | 16 |
| 3 | Intelligent Bio Solutions Inc | 10 |
| 4 | Danaher Corp | 9 |
| 5 | Research Foundation of the State University of New York | 8 |
| 6 | University of London | 8 |
| 7 | Harvard University | 7 |
| 8 | Massachusetts Institute of Technology | 6 |
| 9 | Bayer AG | 4 |
| 10 | Medtronic PLC | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 159 |
| 2 | A61P | Therapeutic activity (drug indications) | 153 |
| 3 | C07J | 47 | |
| 4 | G01N | Investigating / analysing materials | 40 |
| 5 | C07D | Heterocyclic compounds | 30 |
| 6 | Y02A | Climate change adaptation | 20 |
| 7 | A24F | 19 | |
| 8 | A61M | Devices for introducing media into the body | 19 |
| 9 | B82Y | Nanotechnology | 15 |
| 10 | A24B | 13 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| 4-hydroxytestosterone and esters thereof | 1956 | Pfizer Inc | 31 |
| USE OF 4-HYDROXYTESTOSTERONE AS ANGIOGENESIS INHIBITOR | 2022 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Carolyn M. Klinge | University of Louisville | 3 |
| 2 | Boudewijn Burgering | University Medical Center Utrecht | 2 |
| 3 | Wilhelm Schänzer | German Sport University Cologne | 2 |
| 4 | René H. Medema | University Medical Center Utrecht | 2 |
| 5 | Eric W.‐F. Lam | Ludwig Cancer Research | 2 |
| 6 | J. C. Mittler | Veterans Biomedical Research Institute | 2 |
| 7 | Maria Kristina Parr | University of Cologne | 2 |
| 8 | Linda Cheung | University of Warwick | 1 |
| 9 | Penn Muluhngwi | University of Louisville | 1 |
| 10 | Stella Pelengaris | University of Warwick | 1 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Permanent Genetic Access to Transiently Active Neurons via TRAP: Targeted Recombination in Active Populations | 2013 | 763 | Receptor Mechanisms and Signaling |
| Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27 KIP1 | 2000 | 612 | CRISPR and Genetic Engineering |
| Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D | 2002 | 566 | Cell death mechanisms and regulation |
| Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation | 2003 | 374 | Genomics and Chromatin Dynamics |
| Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. | 1996 | 282 | Estrogen and related hormone effects |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 4,17 Beta-dihydroxy-4-androstene-3-one?
Which organizations hold the most patents related to this compound?
What are the main patent classification areas for this compound?
When was the earliest patent for 4-hydroxytestosterone filed, and by whom?
Who are the most prolific authors publishing research on this compound?